Europe
Cellectis has found some sure financial footing that will support its efforts through the remainder of the year. The company secured $163.7 million in an initial public offering to develop CART-T products.
Ferring Pharmaceuticals is buying Rebiotix. As part of the deal, will acquire Rebiotix’s lead program, RBX2660, a non-antibiotic treatment to prevent recurring Clostridium difficile infection (CDI).
Boehringer Ingelheim and OSE Immunotherapeutics signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.
Redx Pharma dosed its first patient for the Porcupine inhibitor RXC004 on February 6. The company indicates it has paused the trial after the first patient dosed had “clinically significant” adverse events.
Allecra Therapeutics released positive top-line data from its Phase II trial of AAI101, an antibiotic against gram-negative bacteria.
Sanofi SA and Evotec AG have teamed up to form an infectious disease research and development program.
John Reed, who for five years has led Roche’s Pharma Research and Early Development (pRED) research group, is stepping down for personal reasons.
The company’s study included 105 kids, ages 7 to 13.
Roche will plunk down $1.9M to acquire Flatiron Health, which has previously been backed by GV, as well as Roche.
Vertex has declined to comment, but BioCentury received a copy of the letter the company sent to laboratories explaining.
PRESS RELEASES